Inhibition of FOXM1 synergizes with BCL2 inhibitor Venetoclax in killing non-t(11;14) multiple myeloma cells through repressing MYC pathway

Despite advancements in the treatment of multiple myeloma, relapsed and refractory MM remains asignificant clinical challenge. FOXM1, a pivotal forkhead box transcription factor, is strongly associated withRRMM, establishing it as a compelling therapeutic target. NB73 is a newly-developed small-molecule inhibitor of FOXM1. Targeting FOXM1, a central player in drug resistance, shows significant potential for enhancing the efficacy of FDA-approved anti-cancer drugs in MM. Our findings that NB73 synergizes with BCL2 inhibitor Venetoclax shed new light on the disappointing outcomes of the Phase-III CANOVA study with a molecular clue.